Angiogenesis

The data will be presented virtually at Angiogenesis, Exudation, and Degeneration 2025 on February 8 and February 10, 2025.

Baruch Kuppermann, MD, PhD, discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular edema and retinal vein occlusion.

Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab, respectively, in branch retinal vein occlusion and central retinal vein occlusion.

Dr. Jennifer Lim reveals new data on Angiopoietin-2 inhibition as a target for addressing nAMD and DME.

In conversation with Ophthalmology Times Europe, Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis.

Dr. Carl Regillo provided an overview of topline results and a deep dive into subgroup analyses of DAVIO 2 trial data.

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants.

This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

The afternoon sessions promise to be engaging and informative in this virtual conference.

This meeting, scheduled for Saturday, February 3, 2024, is a 1-day virtual event sponsored by the Bascom Palmer Eye Institute, Miami, University of Miami Health System.

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Rishi Singh, MD, presented data from the Phase 3 DERBY and OAKS clinical trials for geographic atrophy at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Prof. Anat Loewenstein, MD, shares the latest research on home optical coherence tomography in relation to reactivations and responses in retina patients during her presentation at the virtual Angiogenesis 2023 conference.

Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.

In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”

In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 meeting hosted by Bascom Palmer Eye Institute, Baruch Kupperman, MD, PhD, detailed research in which investigators evaluated risuteganib for safety and effectiveness in patients with dry AMD.

A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.

The Bascom Palmer program showcases neovascular, exudative, and degenerative eye diseases, and is designed for retina specialists, general ophthalmologists, and researchers.

A poll for retina specialists: Let us know if you will be logging on for this annual Bascom Palmer Eye Institute symposium, which will be held virtually on February 10 and 11, 2023.

Presenters at the conference provided new evidence about detecting geography atrophy and wet and dry AMD early and predicting disease progression. Investigators are also focused on finding cures for inherited retinal diseases.

At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wet AMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.

A brief overview of findings presented at the 2022 Angiogenesis, Exudation and Degeneration meeting hosted by Bascom Palmer.

Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.

Dr. Carel Hoyng divulges the main takeaways from his Angiogenesis presentation, including the origins of Stargardt disease, correct diagnosis, ongoing gene therapy trials and the future of therapy.

Dr. Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular edema.

Dr. Arshad M. Khanani reviews the Phase 2 part A results of the KALAHARI study of THR-149 for the treatment of DME.